342PResponse to primary treatment for first recurrence independently influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: A multicenter study of 236 recurrent metastatic patients. (23rd October 2018) - Yamamura, J; Kamigaki, S; Tsujie, M; Fujita, J; Osato, H; Higashi, C; Kanaizumi, H; Tanaka, Y; Hamada, M; Shinzaki, W; Hasimoto, Y; Komoike, Y